4,250.00
+90(+2.16%)
Currency In KRW
Address
Building 203
Seoul, 151-747
Korea, Republic of
Phone
82 2 2102 7200
Website
Sector
Healthcare
Industry
Biotechnology
Employees
132
First IPO Date
December 29, 2005
| Name | Title | Pay | Year Born |
| Mr. Sunyoung Kim D.Phil., Ph.D. | Founder, Chief Executive Officer & Director | 0 | 1955 |
| Mr. Michael Na | Chief Financial Officer & Director of Office of Strategic Net Assessment | 0 | N/A |
| Jun Tae Park Ph.D. | Executive Vice President of Licensing & Regulatory Affairs | 0 | N/A |
| Mr. Seung-Shin Yu Ph.D. | Chief Technology Officer , Representative Director, MD of R&D Center and Intellectual Property & Director | 0 | 1966 |
| Jong-Mook Kim Ph.D. | Director of Devel. Division & Strategic Bus. Division and Director | 0 | 1972 |
| Won Ho Park | Pres | 0 | N/A |
| William O. Frank | Head of Medical | 0 | N/A |
| Miwon Son Ph.D. | Senior Managing Director of Phytotherapeutics | 0 | N/A |
Helixmith Co., Ltd, a biotechnology company, discovers and develops biopharmaceuticals for human diseases. The company has a pipeline of novel biologics and herbal therapeutics in the areas of cardiovascular disease, cancer, and immune disorder, with clinical studies ongoing in the United States, Korea, and China. Its flagship product is VM202, a DNA-based drug for cardiovascular and neurological diseases. The company's pipeline products include VM206, a therapeutic cancer vaccine targeting HER2/neu positive breast or ovarian cancer; and VM501, a re-engineered form of interleukin 11 targeting chemotherapy-induced thrombocytopenia. Its clinical trials biologics comprise VM202-DPN, VM202-PAD, VM501, VM202-ALS, VM202-CAD, and VM206. The company was formerly known as ViroMed Co., Ltd. and changed its name to Helixmith Co., Ltd in April 2019. Helixmith Co., Ltd was incorporated in 1996 and is headquartered in Seoul, South Korea.